Who we are
About us
Launched in September 2024 and funded by the UK charity LifeArc, we are a bold UK-wide initiative working to accelerate diagnosis and develop new treatments for patients with rare respiratory diseases.
Our partnership brings together UK universities, patient organisations, NHS trusts, and UKRI-funded non-profits.
Organisations
Patient organisations
Action for Pulmonary Fibrosis
ChILD UK
LAM Action
Myrovlytis Trust
PCD Research
PCD Support UK
UKRI
Nucleic Acid Therapy Accelerator (NATA) is a UK research initiative helping to develop new RNA and DNA-based treatments. It supports our Centre by offering cutting-edge expertise that could lead to new therapies for rare respiratory diseases where few options currently exist.
About LifeArc
We are funded by LifeArc, a not-for-profit medical research organisation that turns promising scientific research into impact for people living with rare diseases and Global Health infections.
LifeArc forms partnerships and provide scientific expertise and funding to help break down the barriers preventing scientific breakthroughs from becoming life-transforming treatments and cures. They have been doing this for more than 30 years and their work has resulted in five licensed medicines, including cancer drug pembrolizumab and lecanemab for Alzheimer’s disease.
Their goal is a world where no one with a rare disease or a global infectious disease misses out on life-changing innovation because of complexity, cost or risk.
Find out more about LifeArc’s work on www.lifearc.org